Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TG Therapeutics (TGTX)

TG Therapeutics Q1 revenue rises to $63.5 million; raises 2024 BRIUMVI sales guidance

Positive Impact 4 of 5 guidance Written later

TG Therapeutics reported first quarter 2024 total revenue of $63.5 million, up from $7.8 million a year earlier, and a net loss of $10.7 million, down from $39.2 million. The company raised its full-year 2024 U.S. BRIUMVI net product revenue target to $270 million to $290 million, from $220 million to $260 million previously.

Key points

  • Q1 2024 total revenue of $63.5 million, including a $12.5 million milestone payment tied to the first EU launch of BRIUMVI in Germany
  • Q1 2024 U.S. BRIUMVI net product revenue of $50.5 million; company targets approximately $65 million for Q2 2024
  • Net loss of $10.7 million, or $0.07 per share, versus $39.2 million, or $0.28 per share, in Q1 2023
  • Cash, cash equivalents and investment securities of $209.8 million as of March 31, 2024

The filing

CompanyTG Therapeutics (TGTX)
Form8-K, current report
Filed with the SECMay 1, 2024, 7:05 AM ET
Accession number0001437749-24-014062

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.